News
-
Celsius Therapeutics to Present Preclinical Data on Anti-TREM1 Antibody for Inflammatory Bowel Disease at 2023 Crohn’s & Colitis Congress
-
Celsius Therapeutics Names Scientific Advisers
-
Celsius Therapeutics Appoints Sarah Grant, M.D., as Chief Medical Officer
-
Celsius Therapeutics Highlights Recent Accomplishments and Key Initiatives for 2022
-
Servier and Celsius Therapeutics Announce Target Discovery Collaboration in Colorectal Cancer
-
Celsius Therapeutics Signs Research Agreements with Leading Academic Centers to Develop Insights into Inflammatory Bowel Disease Biology